Lakefront Biotherapeutics (LKFT) Common Equity (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Common Equity for 13 consecutive years, with $3.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 31.77% year-over-year to $3.8 billion; the TTM figure through Mar 2026 stood at $3.8 billion (up 31.77% YoY), while the FY2025 annual figure was $3.8 billion, up 21.68% from the prior year.
• Common Equity rose to $3.8 billion in Q1 2026 per LKFT's latest filing, from $3.8 billion in the prior quarter.
• Across five years, Common Equity topped out at $3.8 billion in Q1 2026 and bottomed at $2.6 billion in Q4 2022.
• Historically, Common Equity has averaged $3.1 billion across 5 years, with a median of $3.0 billion in 2025.
• Annual changes were most pronounced in 2022 — Common Equity dropped 14.77% — and 2026, when it jumped 31.77%.
• Lakefront Biotherapeutics' Common Equity stood at $2.6 billion in 2022, then advanced by 16.71% to $3.0 billion in 2023, then grew by 2.92% to $3.1 billion in 2024, then rose by 21.68% to $3.8 billion in 2025, then climbed by 1.12% to $3.8 billion in 2026.
• Business Quant data shows LKFT's Common Equity at $3.8 billion in Q1 2026, $3.8 billion in Q4 2025, and $2.9 billion in Q3 2025.